A Phase 1 interventional study of AVT03 and Prolia in Healthy Male Subjects, sponsored by Alvotech Swiss AG. Completed at 4 sites in 3 countries. Open to male participants aged 28 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-29.
Sponsored by Alvotech Swiss AG · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study has been designed as a randomized, double-blind, single-dose, parallel-group study in healthy adult male subjects 28 years to 55 years old. The study will assess the PK, PD, safety, tolerability and immunogenicity of AVT03 compared to Prolia when administered as a single SC dose.
The study will consist of a 4 week screening period, a 252 day (36 weeks) treatment and assessment period, and an End of Study (EOS) visit on week 36 on Day 252. Subjects will undertake a screening visit between Day -28 and Day -1 to determine their eligibility for the study. On Day 1, eligible subjects will be randomized and will receive a single dose of AVT03 or Prolia as subcutaneous injection.
Alvotech Swiss AG is the lead sponsor of 20 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AVT03 (denosumab) is the proposed biosimilar for Prolia (denosumab). Subjects in this arm will receive a single 60mg dose of AVT03 (denosumab) as a subcutaneous injection.
Biological: AVT03
Prolia(denosumab) is the proposed comparator for AVT03 (denosumab). Subjects in this arm will receive a single 60mg dose of Prolia (denosumab) as a subcutaneous injection.
Biological: Prolia
AVT03 (biosimilar to denosumab) will be given as single subcutaneous injection
Also known as: AVT03, Biosimilar Denosumab
Prolia (denosumab) will be given as single subcutaneous injection
Also known as: Denosumab
Area under the serum concentration-time curve (AUC0-last) from day 0 to day 252
Venous blood samples will be collected for measurement of Area under serum concentration-time curve (AUC 0-t) AVT03 and Prolia
Time frame: Day 1(week 1) to Day 252 (week 36)
Area under the serum concentration-time curve (AUC0-inf) from day 0 to day 252
Venous blood samples will be collected for measurement of CTX-1 serum biomarker for AVT03 and Prolia.
Time frame: Time Frame: Day 1(week 1) to Day 252 (week 36)]
Maximum serum concentration Cmax from day 0 to day 252
Venous blood samples will be collected for measurement of maximum serum concentration (Cmax) of AVT03 and Prolia.
Time frame: Day 1(week 1) to Day 252 (week 36)
PD_AUCE0 for CTX-1 (% inhibition)
Venous blood samples will be collected for measurement of serum concentration of AVT03 and Prolia
Time frame: Day 1(week 1) to Day 252 (week 36)
PK area under the concentration-time curve (AUC0-24) from Day 0 to Day 252
Venous blood samples will be collected for measurement of serum concentration of AVT03 and Prolia
Time frame: Day 1(week 1) to Day 162 (week 24)]
Safety incidence, nature and severity of adverse events
Time frame: Screening to Day 252 (week 36)
Immunogenicity presence and titers of ADAs and presence of nAbs against AVT03 and Prolia
Venous blood samples will be collected for measurement of antidrug-antibodies against of AVT03 and Prolia
Time frame: Time Frame: Day 1(week 1) to Day 252 (week 36)
Ran from Jun 2022 to primary completion in Oct 2023, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AVT03
Alvotech Swiss AG